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   Hemophagocytic lymphohistiocytosis (HLH) is a rare but fatal complication after solid organ transplantation. Acquired forms of HLH 
are described in association with severe sepsis, autoimmune disorders, malignancy, immune-compromised states, infections, and 
solid organ transplantation. We experienced a case of hemophagocytic lymphohistiocytosis after bilateral lung transplantation. Leu-
kopenia, thrombocytopenia, and hyperbilirubinemia were noted and became aggravated 50 days after transplantation. Diagnosis 
of HLH was based on clinical and laboratory findings of splenomegaly, cytopenia, elevated ferritin, elevated interleukin-2 receptor, 
and hemophagocytosis in bone marrow. Other features such as elevated bilirubin, lactate dehydrogenase, and D-dimer which can 
be present in HLH were also noted. The patient was immediately treated with etoposide and dexamethasone. Despite aggressive 
therapy, the patient deteriorated and died. Awareness of the diagnostic criteria of HLH after lung transplantation is important for cli-
nicians.
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■ Case Report ■
Hemophagocytic lymphohistiocytosis (HLH), also known as hemophagocytic syndrome, is a rare and fatal disease that may 
occur in solid organ transplant recipients.[1] This syndrome is characterized by phagocytizing histiocytes that infiltrate tissues 
and phagocytize blood elements and their precursors.[1,2] Genetic forms of HLH are associated with genetic defects in the 
function of natural killer (NK) cells and cytotoxic T cells. Acquired forms of HLH are described in association with severe 
sepsis, autoimmune disorders, malignancy, immune-compromised states, infections, and solid organ transplantation.[3] De-
spite the use of the therapy such as etoposide, cyclosporine, and steroids, the prognosis of this syndrome remains poor.[1,3]
Some cases of reactive HLH after solid organ transplantation have been reported; however, most of the cases were associ-
ated with kidney transplantation. Only a few cases after lung transplantation have been reported.[2,4]
Herein, we report a case of severe HLH after bilateral lung transplantation.
Case Report
 A 60-year-old man who was waiting lung transplantation 
was admitted for aggravation of idiopathic pulmonary fibro-
sis. Previous pulmonary function test showed forced vital 
capacity 32% of predicted value, forced expiratory volume in 
one second 35% of predicted value, total lung capacity 42% 
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of predicted value and lung diffusing capacity for CO 30% 
of predicted value. Despite of treatment, he was worsened 
and in need of ventilator support. However he could not 
undergo bilateral lung transplantation until 2 weeks after 
intubation.
On postoperative day (POD) 25, leukopenia and throm-
bocytopenia were noted and became aggravated. On POD 
33, fever spiking was noted and multifocal ground glass 
opacities and consolidations were demonstrated on chest 
computed tomography. Acute rejection was suspected and 
steroid pulse therapy was performed. After the therapy, the 
chest X-ray result improved, and he was transferred to the 
general ward from the intensive care unit (ICU). His general 
condition was gradually improving.
However, on POD 57, he complained of low-grade fever, 
intermittent chest discomfort, and dyspnea. Echocardiog-
raphy revealed stress-induced cardiomyopathy. He was 
readmitted to the ICU again due to septic and cardiogenic 
shock. Shortly after, he was infected with multidrug resis-
tant Acinetobacter baumannii pneumonia and treated with 
antibiotics (carbapenem, vancomycin, and colistin). Despite 
of the treatment he was worsened, and antifungal agent was 
added. Serum bilirubin had started to rise (total bilirubin 2.1 
mg/dL) from POD 50 and had gradually increased (total bil-
irubin 39.6 mg/dL, direct bilirubin 30.7 mg/dL) by POD 80. 
An abdominal ultrasound demonstrated splenomegaly (11.4 
cm) and a moderate degree of ascites yet no evidence of 
hepatomegaly, intrahepatic duct dilatation, or common bile 
duct dilatation. Acute renal failure was developed and ag-
gravated. Continuous renal replacement therapy was applied 
since POD 68. Pancytopenia was also aggravated (white 
blood cell 1,700/μL, and neutrophils 1,326/μL, hemoglobin 
9.0 g/dL, platelets 46 × 103/μL) (Fig. 1). Fibrinogen (421 
mg/dL; normal range: 200–400 mg/dL), ferritin (4,518 ng/
mL; normal range: 23.9–336.2 ng/mL), and soluble interleu-
kin-2 receptor (8,730 U/mL; normal range: 124–466 U/mL) 
were also elevated. The level of triglyceride was normal (127 
mg/dL, normal range: 48–200 mg/dL). Neurological abnor-
malities or rash were not observed. In the early postopera-
tive period, cytopenia was thought to be related to the use of 
broad-spectrum antibiotics and immunosuppressive drugs. 
Because the cause of ongoing pancytopenia was unclear, we 
conducted bone marrow aspiration and biopsy on POD 82, 
and histiocytes were frequently seen with occasional hemo-
phagocytes (Fig. 2). HLH was diagnosed based on the clini-
cal and laboratory findings, together with the bone marrow 
biopsy results. He was treated immediately with 75 mg/m2 
of etoposide (50% dose reduction due to renal and hepatic 
failure for one day) and 10mg/m2 of dexamethasone (for 3 
days). Four days after, despite aggressive therapy, his condi-
tion severely deteriorated, and he died from vancomycin-
resistant Enterococcus faecium sepsis on POD 87. 
Discussion
HLH is an aggressive and potentially fatal hyper-inflam-
matory syndrome. It results from inappropriate activation 
of lymphocytes and macrophages. Genetic forms of HLH 
are associated with genetic defects in the function of NK 
cells and cytotoxic T cells. Acquired forms of HLH are 
Fig. 1. Complete blood cell count (Fig. 1A) and total bilirubin (Fig. 
1B). Pancytopenia and hyperbilirubinemia became aggravated 
after lung transplantation. WBC: white blood cell; PLT: platelet; 
Hb: hemoglobin; POD:  postoperative day; T. bilirubin: total bili-
rubin.
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caused by infection or other stimuli such as autoimmune 
diseases, malignancies, and acquired immune deficiencies. 
This syndrome is caused from widespread tissue infiltration 
by phagocytizing histiocytes with direct cytotoxicity of ac-
tivated macrophages that infiltrate tissues and phagocytize 
blood elements and their precursors.[1] 
According to the diagnostic guidelines of HLH-2004, a 
diagnosis of HLH can be made with at least five of eight 
criteria: (1) fever, (2) splenomegaly, (3) cytopenia of two or 
more cell lines (hemoglobin, platelets, and neutrophils), (4) 
hypertriglyceridemia or hypofibrinogenemia, (5) elevated 
ferritin, (6) elevated interleukin-2 receptor, (7) decreased 
natural killer cell activity, and (8) hemophagocytosis in bone 
marrow.[1] Current treatment regimens usually involve high 
dose corticosteroids, etoposide and cyclosporine.[1] Despite 
aggressive therapy, HLH is associated with poor prognosis.
[1,3] 
Some cases of reactive HLH after solid organ transplan-
tation have been reported. The first series of transplant 
patients affected with HLH were described by Risdall et al. 
in 1979, who reported that HLH was associated with viral 
infections in 19 patients (including 13 kidney transplant 
recipients).[5] Karras et al. reported that the incidence of 
HLH after kidney transplantation was 0.4% with a mortality 
of 47%.[6] However, only a few cases of HLH after lung 
transplantation have been reported. Oto et al[2] reported a 
case of severe HLH related to Pseudomonas infection in a 
single lobar lung transplant recipient. Diaz-Guzman et al[4] 
reported two patients who developed hemophagocytic lym-
phohistiocytosis after having a lung transplant and presented 
a review of all cases of hemophagocytic lymphohistiocyto-
sis occurring in solid organ transplant recipients. No cause 
was found in the first case, and Epstein-Barr virus was im-
plicated as the causative agent in the second one. 
Fig. 2. Microscopic finding from a bone marrow biopsy specimen 
(Fig. 2A and Fig. 2B) and immunohistochemical staining for CD68 
(Fig. 2C). The microscopic finding from the bone marrow biopsy 
specimen shows prominent hemosiderin deposition and multifocal 
fat necrosis with foamy macrophage infiltrates (Fig. 2A [x100] and 
Fig. 2B [x400]). Immunohistochemical staining for CD68 shows an 
increased number of stromal macrophages (Fig. 2C).
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In this case, a diagnosis of HLH was based on clinical and 
laboratory findings of splenomegaly, cytopenia, elevated 
ferritin, elevated interleukin-2 receptor, and hemophago-
cytosis in bone marrow. Other features such as elevated 
bilirubin, LDH, and D-dimer, which can be present in HLH, 
were also noted. Hyperfibrinogenemia was thought to be 
related to a disseminated intravascular coagulation because 
elevated D-dimer, prothrombine time, and activated partial 
thromboplastin time were also noted. 
HLH and sepsis share high levels of pro- and anti-inflam-
matory molecules and many laboratory findings such as 
cytopenia, elevated ferritin, and hyperbilirubinemia. In fact, 
severe sepsis with multiple organ failure was noted in this 
case finally. However, hemophagocytosis in bone marrow 
was a useful finding for the diagnosis of HLH. 
Opportunistic infections associated with immunocom-
promised status can be the cause of HLH. In patients with 
defined infections, trigger-directed therapy is recommended. 
However, according to HLH-2004 protocol, HLH-specific 
chemotherapy is recommended when HLH is highly sus-
pected, regardless of the forms of HLH (genetic forms or 
acquired forms).[3] So, in our case, concomitant HLH-
directed standard treatment was been administered. 
In conclusion, HLH is an uncommon yet potentially 
lethal complication that may develop in solid organ trans-
plant patients, including lung transplant recipients. Clinical 
presentation is nonspecific, and patients may present with 
unexplained sepsis or multiple organ failure. Therefore, cli-
nicians should consider HLH as a possible diagnosis in the 
clinical context after lung transplantation.
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